Inhibitory immunologicznych punkt ów kontrolnych podziału komórki w leczeniu chorób nowotworowych
Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Aleksandra Mędra, Agata Majchrzak, Piotr Smolewski Despite of great progress in anti-neoplastic treatment the several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanism. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Rzadkie choroby makrofag ów u dorosłych
This article focuses on macrophage disorders which can be present in adult patients. The review highlights pathogenesis, signs and symptoms, diagnostic criteria and principles of therapy in the most frequent macrophage diseases in adults: hemophagocytic lymphohistiocytosis, Rosai-Dorfman disease, Gaucher disease, Niemann-Pick disease, and Langerhans cell histiocytosis. Since macrophage disorders can be encountered by various medical specialists, basic knowledge of these entities and their diagnostic criteria should be familiar to all physicians, including hematologists. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Ponatynib w leczeniu przewlek łej białaczki szpikowej i ostrej białaczki limfoblastycznej z chromosomem Filadelfia
Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Tomasz Sacha Ponatinib is a third generation tyrosine kinase inhibitor (TKI) active against wild type and mutant bcr/abl tyrosine kinase (including T315I). Ponatinib is approved for the treatment of adult patients with T315I mutation detected in CML (all phases) and in Ph+ ALL, for CML patients who are resistant to dasatinib or nilotinib and patients with Ph+ ALL who are intolerant or resistant to dasatinib and for whom subsequent imatinib treatment is not an optimal therapy. In phase II registration study (PACE), 26...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Zmiany rodzaju koncentratu czynnika krzepni ęcia u chorego na hemofilię – korzyść czy ryzyko?
Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Anna Klukowska Patients with haemophilia are treated with a variety of coagulation factor concentrates. They usually change concentrate types many times during their lifetime for different, often independent, reasons. Since recombinant coagulation factor concentrates VIII and IX became available, some patients in well-developed countries have started using these products instead of previously applied plasma-derived concentrates. At the moment, there are different types of concentrates available, including first, seco...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Cz ęść I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane)
Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Jerzy Windyga, Krzysztof Chojnowski, Anna Klukowska, Magdalena Łętowska, Andrzej Mital, Jacek Musiał, Jarosław Peregud-Pogorzelski, Maria Podolak-Dawidziak, Jacek Treliński, Anetta Undas, Tomasz Urasiński, Joanna Zdziarska, Krystyna Zawilska In this document, Working Group for Haemostasis of the Polish Society of Haematology and Blood Transfusion updates the principles of diagnosis and treatment of haemophilia A and B, published for the first time in 2008. In a companion paper (part II),...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Zalecenia Polskiej Grupy Szpiczakowej dotycz ące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016
Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Anna Dmoszyńska, Adam Walter-Croneck, Barbara Pieńkowska-Grela, Lidia Usnarska-Zubkiewicz, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Dominik Dytfeld, Mieczysław Komarnicki, Tadeusz Robak, Artur Jurczyszyn, Joanna Mańko, Aleksander Skotnicki, Sebastian Giebel, Ryszard Czepko, Janusz Meder, Bogdan Małkowski, Krzysztof Giannopoulos New drugs introduced in recent years fo...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Koncentrat p łytek krwi napromieniowany czy poddany redukcji biologicznych czynników chorobotwórczych – który składnik wybrać w celu profilaktyki poprzetoczeniowej choroby przeszczep-przeciw-gospodarzowi?
Publication date: Available online 24 April 2016 Source:Acta Haematologica Polonica Author(s): Piotr Olbromski, Piotr Radziwon Attributable mortality due to transfusion-associated graft-versus-host disease (TA-GVHD) in contrary to the reaction occurring after transplantations has been estimated to be more than 95%. This type of reaction may occur not only in immunocompromised patients but also in patients without immune deficits. Because there is currently no available treatment for TA-GVHD and very high mortality the goal has been to reduce the likelihood of occurrence in recipients at risk of TA-GVHD. The removal...
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Zalecenia dotycz ące oceny schorzeń współistniejących u chorych na przewlekłą białaczkę szpikową w procesie wyboru inhibitora kinaz tyrozynowych
Publication date: Available online 3 July 2016 Source:Acta Haematologica Polonica Author(s): Tomasz Sacha, Sebastian Szmit, Dorota Zozulińska-Ziółkiewicz, Witold Prejzner, Joanna Góra-Tybor Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities....
Source: Acta Haematologica Polonica - July 20, 2016 Category: Hematology Source Type: research
Zalecenia dotyczące oceny schorzeń współistniejących u chorych na przewlekłą białaczkę szpikową w procesie wyboru inhibitora kinaz tyrozynowych
Publication date: Available online 3 July 2016 Source:Acta Haematologica Polonica Author(s): Tomasz Sacha, Sebastian Szmit, Dorota Zozulińska-Ziółkiewicz, Witold Prejzner, Joanna Góra-Tybor Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities....
Source: Acta Haematologica Polonica - July 3, 2016 Category: Hematology Source Type: research
Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane)
Publication date: Available online 28 April 2016 Source:Acta Haematologica Polonica Author(s): Jerzy Windyga, Krzysztof Chojnowski, Anna Klukowska, Magdalena Łętowska, Andrzej Mital, Jacek Musiał, Jarosław Peregud-Pogorzelski, Maria Podolak-Dawidziak, Jacek Treliński, Anetta Undas, Tomasz Urasiński, Joanna Zdziarska, Krystyna Zawilska In this document, Working Group for Haemostasis of the Polish Society of Haematology and Blood Transfusion updates the principles of diagnosis and treatment of haemophilia A and B, published for the first time in 2008. In a companion paper (part II), the ma...
Source: Acta Haematologica Polonica - April 28, 2016 Category: Hematology Source Type: research
Rzadkie choroby makrofagów u dorosłych
This article focuses on macrophage disorders which can be present in adult patients. The review highlights pathogenesis, signs and symptoms, diagnostic criteria and principles of therapy in the most frequent macrophage diseases in adults: hemophagocytic lymphohistiocytosis, Rosai-Dorfman disease, Gaucher disease, Niemann-Pick disease, and Langerhans cell histiocytosis. Since macrophage disorders can be encountered by various medical specialists, basic knowledge of these entities and their diagnostic criteria should be familiar to all physicians, including hematologists. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - April 27, 2016 Category: Hematology Source Type: research
Nowe metody diagnostyczne w prognozowaniu i śledzeniu odpowiedzi na leczenie inhibitorami kinaz tyrozynowych przewlekłej białaczki szpikowej
Publication date: Available online 28 April 2016 Source:Acta Haematologica Polonica Author(s): Joanna Wącław, Tomasz Sacha Techniques of molecular biology are of key importance in diagnostics and monitoring of tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML). Although much has already been achieved in this field, new prognostic factors and developments in laboratory methods are constantly emerging. Halving time is a new prognostic factor defined as the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Among patients ...
Source: Acta Haematologica Polonica - April 27, 2016 Category: Hematology Source Type: research
Interferon γ i interleukina-2 a ostra choroba przeszczep-przeciw-gospodarzowi i powikłania infekcyjne u pacjentów po allogenicznej transplantacji komórek krwiotwórczych
Conclusion Serum concentration of IFN-γ following alloHSCT gradually increases. High serum concentration of IFN-γ is related to infectious complications rather than to acute GvHD. Undetectable serum concentration of IL-2 in majority of patients prevents from drawing conclusions. (Source: Acta Haematologica Polonica)
Source: Acta Haematologica Polonica - April 24, 2016 Category: Hematology Source Type: research
Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych
Publication date: Available online 25 April 2016 Source:Acta Haematologica Polonica Author(s): Aleksandra Mędra, Agata Majchrzak, Piotr Smolewski Despite of great progress in anti-neoplastic treatment several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanisms. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged in the im...
Source: Acta Haematologica Polonica - April 24, 2016 Category: Hematology Source Type: research
Koncentrat płytek krwi napromieniowany czy poddany redukcji biologicznych czynników chorobotwórczych – który składnik wybrać w celu profilaktyki poprzetoczeniowej choroby przeszczep-przeciw-gospodarzowi?
Publication date: Available online 24 April 2016 Source:Acta Haematologica Polonica Author(s): Piotr Olbromski, Piotr Radziwon Attributable mortality due to transfusion-associated graft-versus-host disease (TA-GVHD) in contrary to the reaction occurring after transplantations has been estimated to be more than 95%. This type of reaction may occur not only in immunocompromised patients but also in patients without immune deficits. Because there is currently no available treatment for TA-GVHD and very high mortality the goal has been to reduce the likelihood of occurrence in recipients at risk of TA-GVHD. The removal...
Source: Acta Haematologica Polonica - April 23, 2016 Category: Hematology Source Type: research
